Decision and Details
Korean Intellectual Property Office (KIPO)Grant of a patent in Korea for a TRPV4 antagonist (pyrimidin-4(3H)-one derivative)
The compound patent that had been under examination in Korea was determined to cover an invention worthy of patent protection. The decision will further strengthen the company's intellectual property rights.
There will be no impact on the company's results for the fiscal year ending December 2026. The company believes this will contribute to an increase in corporate value over the medium to long term.
| Item | Details |
|---|---|
| Matter Covered | Grant of a patent in Korea for a TRPV4 antagonist (pyrimidin-4(3H)-one derivative) |
| Decision-Making Body | Korean Intellectual Property Office (KIPO) |
| Decision Date | 2 September 2026 (the date the company was notified of the grant) |
| Quantity / scale | Application No. 10-2022-7040115; patent granted by all five major patent offices |
| Impact on Business Performance | There will be no impact on the company's results for the fiscal year ending December 2026. The company believes this will contribute to an increase in corporate value over the medium to long term. |
| Reason | The compound patent that had been under examination in Korea was determined to cover an invention worthy of patent protection. The decision will further strengthen the company's intellectual property rights. |
| Related previous disclosures | 1 April 2021: “Notice of Execution of Agreement to Establish a Joint Research Course with Gifu Pharmaceutical University”; 24 February 2023: “Notice of Publication of Paper on TRPV4 Antagonist” |
| Future plans | The patent will become registered upon payment of the patent fee following the grant. The company aims to contribute to an increase in corporate value over the medium to long term through future development and other activities. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The examination in Korea has been completed, and the invention was determined to be worthy of patent protection. The company explains that this grant will further strengthen its intellectual property rights.